New Two-Drug combo challenges standard care for returning blood cancer
NCT ID NCT07463807
Summary
This study aims to see if a new two-drug combination (teclistamab and pomalidomide) works better than the current standard three-drug treatment for multiple myeloma that has come back after initial therapy. It will involve about 162 adults whose cancer has relapsed after one or two prior treatments. The main goal is to see if the new combination can reduce cancer cells to undetectable levels more effectively and with manageable side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.